MedTrace Logo

News Related to gene therapy

Related coverage linked through entity extraction aliases.

Johnson & Johnson Invests $1 Billion in Cell Therapy Manufacturing Facility

Apr 01, 2026

Johnson & Johnson invests over $1 billion in a new Pennsylvania cell therapy manufacturing facility for cancer and neurological diseases. The expansion addresses growing demand for advanced therapies while highlighting workforce training challenges in GMP environments. Other developments include new cell line technology for viral vector production and CRISPR-edited CAR-T manufacturing partnerships.

Transformative Therapies Advance Treatment for Sickle Cell Disease

Apr 02, 2026

Transformative therapies including stem cell transplant and gene therapy offer sickle cell disease patients potential freedom from the SCD phenotype with reduced morbidities. About 90% of patients successfully switch to donor blood cell production after transplant, while gene therapies work by editing the patient's own stem cells. These treatments require careful consideration of disease severity and potential risks including major adverse events.

FDA Drops Two-Study Requirement for Drug Approvals to Speed Access

Apr 02, 2026

The FDA will drop its longtime requirement for two rigorous studies to approve new drugs, moving to a default position of requiring only one study. Commissioner Marty Makary says the change reflects modern scientific advances and aims to accelerate drug availability without compromising safety. The shift follows decades of increasing flexibility for rare and fatal diseases, with about 60% of first-of-a-kind drugs already approved based on single studies in recent years.

Clinical Trial Costs and Phases: From Safety Testing to Market Approval

Mar 31, 2026

Clinical trials take 10-15 years and cost $1-2 billion from discovery to approval, progressing through four phases from safety testing to real-world monitoring. These studies face challenges including high costs, regulatory oversight, and participant recruitment while new technologies are transforming trial design. Illinois faces a shortage of Phase I clinical trial facilities despite local companies conducting over 50 such trials annually.

Ocugen Reports Phase 2 Data for Geographic Atrophy Gene Therapy OCU410

Mar 24, 2026

Ocugen reported Phase 2 data for its geographic atrophy gene therapy OCU410 showing 31% lesion growth reduction versus control. The company plans Phase 3 initiation in Q3 2026 and maintains its goal of three BLA filings in three years. Shares fell 11.48% following the data release which trailed earlier interim results.

Ocular Therapeutix's Axpaxli Outperforms Eylea in Wet AMD Trial

Mar 24, 2026

Ocular Therapeutix's experimental drug Axpaxli showed superior vision maintenance compared to Regeneron's Eylea in a late-stage wet AMD trial. Meanwhile, Ocugen reported 12-month data showing its gene therapy OCU410 reduced geographic atrophy lesions by 31%, though less than earlier interim results. Both companies are advancing toward regulatory submissions and further clinical development.

Orphan Drugs Market Projected to Reach $486.51 Billion by 2032

Mar 23, 2026

The global orphan drugs market is projected to grow from $223.76 billion in 2023 to $486.51 billion by 2032, with North America leading at 38% market share. Over 500 orphan drugs are approved with more than 800 candidates in clinical trials, driven by regulatory incentives and major pharmaceutical company investments in rare disease therapies.

Sarepta Therapeutics Receives FDA Feedback and New Zealand Trial Approval

Mar 23, 2026

Sarepta Therapeutics received FDA feedback supporting supplemental applications for AMONDYS 45 and VYONDYS 53, while New Zealand approved a Phase 1 trial for Huntington's Disease candidate SRP-1005. The company faces significant share price declines despite these developments, with analysts showing wide disagreement on valuation targets ranging from $5 to $80.

uniQure Faces FDA Setback, Lawsuits Over AMT-130 as Fabry Program Advances

Mar 02, 2026

uniQure received FDA feedback stating current AMT-130 data unlikely to support accelerated approval for Huntington's disease, while securities fraud lawsuits challenge prior disclosures. Fresh Fabry disease trial data showed elevated enzyme activity but prompted a dosing pause for safety review.